Jean-Charles Soria, Head of Oncology Therapeutic Area at Amgen, posted on LinkedIn:
“For years, KRAS remained one of the most challenging targets in cancer research. In fact, many believed it was impossible to target.
Amgen scientists are relentless about pushing the boundaries of science. They pioneered game-changing research into KRAS G12C, a mutation that drives cancer growth for some patients with tough-to-treat cancers like NSCLC and mCRC.
Now, with two FDA-approved treatments targeting KRAS G12C, My Company continues to explore new frontiers to bring hope to patients.
Learn more at FindKRASG12C.com.”
